R&D is the core of our innovation
In 2021, we invested £5.3 billion in R&D – 3.5% AER more than 2020 - to enhance our pipeline of vaccines and medicines and help us get ahead of disease together.
To keep up this pace, we have also streamlined our R&D governance. In 2021, we moved from separate clinical development organisations for vaccines and medicines into a single combined organisation. This move will help us make sure we invest in programmes that can most positively impact the health of patients by unlocking scientific synergies across prevention and treatment.
How our R&D approach is getting us ahead of disease
Vaccines and medicines that are currently in development60+
Major new vaccines and medicines approved since mid 201713
In the last five years the number of assets in phase III increased byx2
We cut the overall cycle times across development by20%
Why do we prioritise genetically validated targets in our R&D?
Scientific research shows that genetically validated targets are at least twice as likely to successfully become medicines.
That’s why 70% of our research targets are now genetically validated.
What therapeutic areas are we focusing on?
We prioritise research into vaccines and medicines across our four core therapeutic areas of infectious diseases, HIV, oncology, and immunology. We also remain open to opportunities outside of these core areas where the science aligns with our strategic approach. We continue to strengthen our pipeline of vaccines and medicines, applying our growing expertise and partnerships in technology and data to increase the productivity of our R&D.
For 70 years we have been pioneering research to help protect people from infectious disease.
We are working to treat, prevent and ultimately cure HIV.
Our expertise in oncology allows us to bring groundbreaking cancer therapies to patients in need.
We’re focused on unlocking the science of the immune system to understand the body’s defence system.
We are committed to pursuing other science-led opportunities outside of our four core therapy areas.